In particular, MCL-1 inhibition, which is now attainable clinically as a potent BH3 inhibitor was recently characterized and shown to be tolerable [34], might be particularly appropriate as it should counteract the effect of a pathological stroma on cancer cells in the same time as it should affect stromal cells that produce this effect. Here, MCL1 is linked to cancer.